Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 12 500 UNITS IN SODIUM CHLORIDE 0 9 versus MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 12 500 UNITS IN SODIUM CHLORIDE 0 9 versus MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER.
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9% vs MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, potentiating its inhibition of factor Xa and thrombin, thereby preventing fibrin formation and thrombus propagation.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
For treatment of venous thromboembolism: Initial IV bolus of 80 units/kg, then continuous IV infusion at 18 units/kg/hour. For prophylaxis: Subcutaneous injection of 5000 units every 8-12 hours. Heparin sodium 12,500 units/250 mL (50 units/mL) is typically used for continuous IV infusion.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
None Documented
None Documented
Terminal elimination half-life is dose-dependent: for bolus doses of 100, 400, and 800 U/kg, half-lives are approximately 1, 2.5, and 5 hours, respectively. In severe renal impairment, half-life may be prolonged.
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Renal (primarily via reticuloendothelial system depolymerization; elimination of metabolites in urine; minimal unchanged drug excreted renally). Approximately 50% of a dose is eliminated renally as metabolites.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Category A/B
Category C
Electrolyte
Electrolyte